Institute of Clinical Medical Sciences, China‑Japan Friendship Hospital, Beijing 100029, P.R. China.
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100029, P.R. China.
Int J Mol Med. 2024 Nov;54(5). doi: 10.3892/ijmm.2024.5428. Epub 2024 Sep 20.
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end‑stage renal disease, and is characterized by persistent proteinuria and decreased glomerular filtration rate. Despite extensive efforts, the increasing incidence highlights the urgent need for more effective treatments. Histone methylation is a crucial epigenetic modification, and its alteration can destabilize chromatin structure, thereby regulating the transcriptional activity of specific genes. Histone methylation serves a substantial role in the onset and progression of various diseases. In patients with DKD, changes in histone methylation are pivotal in mediating the interactions between genetic and environmental factors. Targeting these modifications shows promise in ameliorating renal histological manifestations, tissue fibrosis and proteinuria, and represents a novel therapeutic frontier with the potential to halt DKD progression. The present review focuses on the alterations in histone methylation during the development of DKD, systematically summarizes its impact on various renal parenchymal cells and underscores the potential of targeted histone methylation modifications in improving DKD outcomes.
糖尿病肾病(DKD)是慢性肾脏病和终末期肾病的主要病因,其特征是持续蛋白尿和肾小球滤过率降低。尽管进行了广泛的努力,但发病率的上升突出表明需要更有效的治疗方法。组蛋白甲基化是一种重要的表观遗传修饰,其改变可以使染色质结构不稳定,从而调节特定基因的转录活性。组蛋白甲基化在各种疾病的发生和进展中起着重要作用。在 DKD 患者中,组蛋白甲基化的变化在介导遗传和环境因素之间的相互作用中起着关键作用。针对这些修饰有望改善肾脏组织学表现、组织纤维化和蛋白尿,为阻止 DKD 进展提供了一个新的治疗前沿。本综述重点关注 DKD 发展过程中组蛋白甲基化的改变,系统总结了其对各种肾实质细胞的影响,并强调了靶向组蛋白甲基化修饰改善 DKD 结局的潜力。